Vergoeding 2020-2024 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 37.694 | 12.925 | 8.866 | 1.140 | 3.026 |
| J05AP08 Sofosbuvir (Sovaldi ®) | 189.850 | 100.710 | 77.960 | 107.190 | 29.235 |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | 279.400 | 151.400 | 112.070 | 50.136 | 104.560 |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | 1.168.800 | 580.340 | 425.570 | 423.210 | 449.920 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | 2.119.800 | 1.793.500 | 2.134.800 | 1.574.300 | 1.187.400 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | 299.300 | 436.330 | 549.390 | 218.260 | 128.630 |
| J05AP57 Glecaprevir met pibrentasvir (Maviret ®) | 7.216.000 | 7.589.200 | 6.183.600 | 5.551.900 | 5.874.900 |
| Totaal | 11.310.844 | 10.664.405 | 9.492.256 | 7.926.136 | 7.777.671 |